Skip to main content
SpringerLink
Log in

Origin and impact of plasmid-mediated extended-spectrum beta-lactamases

  • Review
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Resistance to oxyimino cephalosporins was originally highlighted by the emergence of plasmid-encoded extended-spectrum β-lactamases deriving by mutation from TEM-1, TEM-2 and SHV type enzymes (class A). The broader spectrum of resistance produced by these enzymes is related to more amino acid substitutions, but susceptibility to seven alpha-methoxyimino cephalosporins and carbapenems was preserved until recently. Clavulanate-sensitive extended-spectrum β-lactamases are distributed worldwide, mainly amongKlebsiella pneumoniae isolates. Novel clavulanate-sensitive extended-spectrum β-lactamases deriving from other class A enzymes (e.g. MEN-1 from βla OXY, OXA-11 inPseudomonas aeruginosa from PSE-2) have been reported. Recently, clavulanate-resistant extended-spectrum β-lactamases (class C) were encountered amongst single isolates, mostlyKlebsiella pneumoniae. These cephalosporinases or cefamycinases (usually chromosomally mediated) have expanded the spectrum of plasmid-encoded resistance to include seven alpha-methoxyimino cephalosporins. Thus far, only two isolates (1Pseudomonas aeruginosa, 1Bacteroides fragilis), both recovered in Japan, with plasmid-mediated resistance to carbapenems have been found.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Philippon A, Labia R, Jacoby GA: Extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1989, 33: 1131–1136.

    CAS  PubMed  Google Scholar 

  2. Jacoby GA, Medeiros AA: More extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1991, 35: 1697–1704.

    CAS  PubMed  Google Scholar 

  3. Bauernfeind A, Chong Y, Schweighart S: Extendedbroad-spectrum β-lactamase inKlebsiella pneumoniae including resistance to cephamycins. Infection 1989, 17: 316–321.

    Article  CAS  PubMed  Google Scholar 

  4. Bernard H, Tancrède C, Livrelli V, Morand A, Barthélémy M, Labia R: A novel plasmid-mediated extended-spectrum β-lactamase not derived from TEM-or SHV-type enzymes. Journal of Antimicrobial Chemotherapy 1992, 28: 590–592.

    Google Scholar 

  5. Hall LMC, Livermore DM, Gür D, Akova M, Akalin HE: OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase fromPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1993, 37: 1637–1644.

    CAS  PubMed  Google Scholar 

  6. Horii T, Arakawa Y, Ohta M, Ichiyama S, Wacharotayankun R, Kato N: Plasmid-mediated AmpC-type β-lactamase isolated fromKlebsiella pneumoniae confers resistance to broad-spectrum β-lactams, including moxalactam. Antimicrobial Agents and Chemotherapy 1993, 37: 984–990.

    CAS  PubMed  Google Scholar 

  7. Matsumoto Y, Ikeda, F, Kamimura T, Yokota Y, Mine Y: Novel plasmid-mediated β-lactamase fromEscherichia coli that inactivates oxyimino-cephalosporins. Antimicrobial Agents and Chemotherapy 1988, 32: 1243–1246.

    CAS  PubMed  Google Scholar 

  8. Papanicolaou GA, Medeiros AA, Jacoby GA: Novel plasmid-mediated β-lactamase (MIR-1) conferring resistance to oxyimino-and a-methoxy β-lactams in clinical isolates ofKlebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 1990, 34: 2200–2209.

    CAS  PubMed  Google Scholar 

  9. Payne DJ, Woodford N, Amyes SGB: Characterization of the plasmid-mediated β-lactamase BIL-1. Journal of Antimicrobial Chemotherapy 1992, 30: 119–127.

    CAS  PubMed  Google Scholar 

  10. Tzouvelekis LS, Tzelepi E, Mentis AF, Tsakris A: Identification of a novel plasmid-mediated β-lactamase with chromosomal cephalosporinase characteristics fromKlebsiella pneumoniae. Journal of Antimicrobial Chemotherapy 1993, 31: 645–654.

    CAS  PubMed  Google Scholar 

  11. Watanabe Y, Yokota T, Higashi Y, Wakai Y, Mine Y: In vitro and in vivo transferable β-lactam resistance due to a new plasmid-mediated oxyimino cephalosporinase from a clinical isolate ofProteus mirabilis. Microbiology and Immunology 1991, 35: 87–97.

    CAS  PubMed  Google Scholar 

  12. Bandoh K, Watanabe K, Muto Y, Tanaka Y, Kato N, Ueno K: Conjugal transfer of imipenem resistance inBacteroides fragilis. Journal of Antibiotics 1992, 45: 542–547.

    CAS  PubMed  Google Scholar 

  13. Watanabe Y, Iyobe S, Inoue M, Mitsuhashi S: Transferable imipenem resistance inPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1991, 35: 147–151.

    CAS  PubMed  Google Scholar 

  14. Bush K: A Classification of β-lactamases: groups 1, 2a, 2b, and 2b′. Antimicrobial Agents and Chemotherapy 1989, 33: 264–270.

    CAS  PubMed  Google Scholar 

  15. Ambler RP: The structure of β-lactamases. Philosophical Transactions of the Royal Society of London (B Biological Sciences) 1980, 289: 321–331.

    CAS  Google Scholar 

  16. Huletsky A, Couture F, Levesque RC: Nucleotide sequence and phylogeny of SHV-2 β-lactamase. Antimcrobial Agents and Chemotherapy 1990, 34: 1725–1732.

    CAS  Google Scholar 

  17. Arlet G, Rouveau M, Bengoufa D, Nicolas MH, Philippon A: Novel transferable extended-spectrum β-lactamase (SHV-6) fromKlebsiella pneumoniae conferring selective resistance to ceftazidime. FEMS Microbiological Letters 1991, 81: 57–62.

    CAS  Google Scholar 

  18. Arlet G, Rouveau M, Fournier G, Lagrange PH, Philippon A: Novel, plasmid-encoded, TEM-derived extended-spectrum β-lactamase inKlebsiella pneumoniae conferring higher resistance to aztreonam than to extended-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy 1993, 37: 2020–2023.

    CAS  PubMed  Google Scholar 

  19. Barthélémy M, Peduzzi J, Ben Yaghlane H, Labia R: Single amino acid substitution between SHV-1 β-lactamase and cefotaxime-hydrolyzing SHV-2 enzyme. FEBS Microbiological Letters 1988, 231: 217–220.

    Article  Google Scholar 

  20. Chanal C, Poupart MC, Sirot D, Labia R, Sirot J, Cluzel RA: Nucleotide sequences of CAZ-2, CAZ-6, and CAZ-7 β-lactamase genes. Antimicrobial Agents and Chemotherapy 1992, 36: 1817–1820.

    CAS  PubMed  Google Scholar 

  21. Collatz E, Tran Van Nhieu G, Billot-Klein D, Williamson R, Gutmann L: Substitution of serine for arginine in position 162 of TEM-type β-lactamases extends the substrate profile of mutant enzymes, TEM-7 and TEM-101, to ceftazidime and aztreonam. Gene 1989, 78: 349–354.

    Article  CAS  PubMed  Google Scholar 

  22. Nicolas MH, Jarlier V, Philippon A, Cole S: Molecular cloning of the gene SHV-3 responsible for transferable cefotaxime resistance in clinical isolates ofKlebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 1989, 33: 2096–2100.

    CAS  PubMed  Google Scholar 

  23. Sougakoff, W, Goussard S, Gerbaud G, Courvalin P: Plasmid-mediated-resistance to third-generation cephalosporins due to point mutations in TEM-type penicillinase genes. Reviews of Infectious Diseases 1988, 10: 879–884.

    CAS  PubMed  Google Scholar 

  24. Sougakoff W, Petit A, Goussard J, Sirot D, Buré A, Courvalin P: Characterization of the plasmid genes blaT-4 and blaT-5, which encode the broad spectrum β-lactamases TEM-4 and TEM-5 inEnterobacteriaceae. Gene 1989, 78: 339–348.

    Article  CAS  PubMed  Google Scholar 

  25. Chanal CM, Sirot DL, Petit A, Labia R, Morand A, Sirot JL, Cluzel RA: Multiplicity of TEM-derived β-lactamases fromKlebsiella pneumoniae isolated at the same hospital and relationships between the responsible plasmids. Antimicrobial Agents and Chemotherapy 1989, 33: 1915–1920.

    CAS  PubMed  Google Scholar 

  26. Poupart MC, Chanal C, Sirot D, Labia R, Sirot J: Identification of CTX-2 a novel cefotaximase from aSalmonella mbandaka isolate. Antimicrobial Agents and Chemotherapy 1991, 35: 1498–1500.

    CAS  PubMed  Google Scholar 

  27. Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R: Transferable resistance to third-generation cephalosporins in clinical isolates ofKlebsiella pneumoniae. Identification of CTX-1, a novel beta-lactamase. Journal of Antimicrobial Chemotherapy 1987, 20: 323–334.

    CAS  PubMed  Google Scholar 

  28. Sirot J, Chanal C, Petit A, Sirot D, Labia R, Gerbaud G:Klebsiella pneumoniae and otherEnterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies. Reviews of Infectious Diseases 1988, 10: 850–859.

    CAS  PubMed  Google Scholar 

  29. Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J: Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistantKlebsiella pneumoniae. Lancet 1987, ii: 302–306.

    Article  Google Scholar 

  30. Philippon A, Ben Redjeb S, Fournier G, Ben Hassen A: Epidemiology of extended-spectrum β-lactamases. Infection 1989, 17: 347–354.

    Article  CAS  PubMed  Google Scholar 

  31. Jacoby GA, Carreras I: Activities of β-lactam antibiotics againstEscherichia coli strains producing extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1990, 34: 858–862.

    CAS  PubMed  Google Scholar 

  32. Kitzis MD, Liassine N, Ferré B, Gutmann L, Acar JF, Goldstein F: In vitro activities of 15 oral β-lactams againstKlebsiella pneumoniae harboring new extendedspectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1990, 34: 1783–1786.

    CAS  PubMed  Google Scholar 

  33. Jarlier V, Nicolas MH, Fournier G, Philippon A: Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactams inEnterobacteriaceae: hospital prevalence and susceptibility patterns. Reviews of Infectious Diseases 1988, 10: 867–878.

    CAS  PubMed  Google Scholar 

  34. Legrand P, Fournier G, Buré A, Jarlier V, Nicolas MH, Decré D, Duval J, Philippon A: Detection and distribution of extended broad-spectrum β-lactamases inEnterobacteriacae in four French hospitals. European Journal of Clinical Microbiology and Infectious Diseases 1989, 8: 527–529.

    Article  CAS  Google Scholar 

  35. Philippon A, Fournier G, Paul G, Vedel G, Névot P: Détection et distribution des β-lactamases à spectre élargi chez les entérobactéries. Médecine et Maladies Infectieuses 1988, 12: 869–876.

    Article  Google Scholar 

  36. Ben Redjeb S, Ben Yaghlane H, Boujnah A, Philippon A, Labia R: Synergy between clavulanic acid and newer β-lactams on 9 clinical isolates ofKlebsiella pneumoniae, Escherichia coli andSalmonella typhimurium resistant to third generation cephalosporins. Journal of Antimicrobial Chemotherapy 1988, 21: 263–266.

    CAS  PubMed  Google Scholar 

  37. Buré A, Legrand P, Arlet G, Jarlier V, Paul G, Philippon A: Dissemination ofKlebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam in five French hospitals. European Journal of Clinical Microbiology and Infectious Diseases 1988, 7: 780–782.

    Article  Google Scholar 

  38. Gutmann L, Ferré B, Goldstein F, Risk N, Acar JF, Collatz E: SHV-5, A novel SHV-type β-lactamase that hydrolyzes broad-spectrum cephalosporins and monobactams. Antimicrobial Agents and Chemotherapy 1989, 33: 951–956.

    CAS  PubMed  Google Scholar 

  39. Goussard S, Sougakoff W, Mabilat C, Bauernfeind A, Courvalin P: An IS1-like element is responsible for high-level synthesis of extended-spectrum β-lactamase TEM-6 inEnterobacteriaceae. Journal of General Microbiology 1991, 137: 2681–2687.

    CAS  PubMed  Google Scholar 

  40. Vedel G, Mabilat C, Goussard S, Picard B, Fournier G, Gilly L, Paul G, Philippon A: Two variants of transferable extended-spectrum TEM-β-lactamase successively isolated from anEscherichia coli isolate. FEMS Microbiological Letters 1992, 93: 161–166.

    CAS  Google Scholar 

  41. Smith CE, Tillman BS, Howell AW, Longfield RN, Jorgensen JH: Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due toKlebsiella pneumoniae producing an extended-spectrum β-lactamase. Antimicrobial Agents and Chemotherapy 1990, 34: 1290–1293.

    CAS  PubMed  Google Scholar 

  42. Naumoski L, Ouinn JP, Miyashiro D, Patel M, Bush K, Singer SB, Graves D, Palzkill T, Arvin AN: Out-break of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrobial Agents and Chemotherapy 1992, 36: 1991–1996.

    Google Scholar 

  43. Gutmann L, Kitzis MD, Billot-Klein D, Goldstein F, Tran Van Nhieu G, Lu T, Carlet J, Collatz E, Williamsom R: Plasmid-mediated β-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam. Reviews of Infectious Diseases 1988, 10: 860–866.

    CAS  PubMed  Google Scholar 

  44. Thabaut A, Acar J, Allouch G, Arlet G, Berardi-Grassias L, Bergogne-Bérézin E, Brun Y, Buisson Y, Chabanon G, Cluzel R, Courtieu A, Dabernat H, Duval J, Fleurette J, Ghnassia JC, Jarlier V, Meyran M, Monteil H, Petithory JC, Philippon A, Reverdy ME, Reynaud A, Sedaillan A, Sirot J, Werneburg B: Fréquence et distribution des béta-lactamases chez 1792 souches deKlebsiella pneumoniae isolées en France entre 1985 et 1988. Pathologie et Biologie 1990, 38: 459–463.

    CAS  PubMed  Google Scholar 

  45. Sirot DL, Goldstein FW, Soussy CJ, Courtieu AL, Husson MO, Lemozy J, Meyran M, Morel C, Perez R, Quentin-Noury C, Reverdy ME, Scheftel JM, Rosembaum M, Rezvany Y: Resistance to cefotaxime and seven other β-lactams in members of the familyEnterobacteriaceae: a 3-year survey in France. Antimicrobial Agents and Chemotherapy 1993, 36: 1677–1681.

    Google Scholar 

  46. Richard C, Philippon A, M'Boup S, Vieu JF: Epidémiologie des infections pédiatriques àKlebsiella dans deux hôpitaux de Dakar: production de β-lactamases à spectre élargi (1987–1988). Médecine et Maladies Infectieuses 1989, 19: 753–759.

    Article  Google Scholar 

  47. Vatopoulos AC, Philippon A, Tzouvelekis LS, Legakis NJ, Komninou Z: Prevalence of a transferable SHV-5 beta-lactamase in clincal isolates ofKlebsiella pneumoniae andEscherichia coli in Greece, Journal of Antimicrobial Chemotherapy 1991, 26: 635–648.

    Google Scholar 

  48. Gür D, Pitt TL, Hall LM, Erdal Akalin H, Livermore DM: Diversity of klebsiellae with extended-spectrum β-lactamases at a Turkish university hospital. Journal of Hospital Infection 1992, 22: 163–178.

    Article  PubMed  Google Scholar 

  49. Liu PYF, Gür D, Hall LMC, Livermore D: Survey of the prevalence of β-lactamases amongst 1000 gramnegative bacilli isolated consecutively at the Royal London Hospital. Journal of Antimicrobial Chemotherapy 1992, 30: 429–447.

    CAS  PubMed  Google Scholar 

  50. Vernet V, Madoulet C, Bajolet O, Philippon A: Incidence of two virulence factors (aerobactin and mucoid phenotype) among 190 clinical isolates ofKlebsiella pneumoniae producing extended-spectrum β-lactamases. FEMS Microbiological Letters 1992, 96: 1–6.

    CAS  Google Scholar 

  51. Darfeuille-Michaud A, Jallat C, Aubel D, Sirot D, Rich C, Sirot J, Joly B: R-plasmid-encoded adhesive factor inKlebsiella pneumoniae strains responsible for human nosocomial infections. Infection and Immunity 1992, 60: 44–55.

    CAS  PubMed  Google Scholar 

  52. Mabilat C, Courvalin P: Development of “oligotyping” for characterization and molecular epidemiology of TEM β-lactamases in members of the familyEnterobacteriaceae. Antimicrobial Agents and Chemotherapy 1990, 34: 2210–2216.

    CAS  PubMed  Google Scholar 

  53. Shah PM, Stille W:Escherichia coli andKlebsiella pneumoniae strains more susceptible to cefoxitin than to third generation cephalosporins. Journal of Antimicrobial Chemotherapy 1983, 11: 597–598.

    CAS  PubMed  Google Scholar 

  54. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B: Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy 1985, 28: 302–307.

    CAS  PubMed  Google Scholar 

  55. Fernandez-Rodriguez A, Canton R, Perez-Diaz JC, Martinez Beltran J, Picazo JJ, Baquero F: Aminoglycoside-modifying enzymes in clinical isolates harboring extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1992, 36: 2536–2538.

    CAS  PubMed  Google Scholar 

  56. Labia R, Morand A, Tiwari K, Pitton JS, Sirot D, Sirot J: Kinetic properties of two plasmid-mediated β-lactamases fromKlebsiella pneumoniae with a strong activity against third-generation cephalosporins. Journal of Antimicrobial Chemotherapy 1988, 21: 301–307.

    CAS  PubMed  Google Scholar 

  57. Mulgrave L: Extended broad-spectrum β-lactamases in Australia. Medical Journal of Australia 1990, 152: 444–445.

    Google Scholar 

  58. Petit AG, Gerbaud G, Sirot D, Courvalin P, Sirot J: Molecular epidemiology of TEM-3 (CTX-1) β-lactamase. Antimicrobial Agents and Chemotherapy 1990, 34: 219–224.

    CAS  PubMed  Google Scholar 

  59. Arlet G, Sanson-le Pors MJ, Rouveau M, Fournier G, Marie O, Schlemmer B, Philippon A: Nosocomial outbreak of infections due toKlebsiella pneumoniae that produce SHV-4 β-lactamase. European Journal of Clinical Microbiology and Infectious Diseases 1990, 9: 797–803.

    Article  CAS  Google Scholar 

  60. Bingen E, Desjardins P, Arlet G, Bourgeois F, Mariani-Kurkdjian P, Lambert-Zechovsky N, Denamur E, Philippon Elion J: Molecular epidemiology of plasmid spread among extended broad-spectrum β-lactamase producingKlebsiella pneumoniae in a pediatric hospital. Journal of Clinical Microbiology 1993, 31: 179–184.

    CAS  PubMed  Google Scholar 

  61. Coovadia YM, Johnson AP, Bhana RH, Hutchinson GR, George RC, Hafferjee IE: MultiresistantKlebsiella pneumoniae in a neonatal nursery: the importance of maintenance of infection control policies and procedures in the prevention of outbreaks. Journal of Hospital Infection 1992, 22: 197–205.

    Article  CAS  PubMed  Google Scholar 

  62. de Champs C, Sirot D, Chanal C, Poupart MC, Dumas MP, Sirot J: Concomitant dissemination of three extended-spectrum β-lactamases among differentEnterobacteriaceae isolated in a French hospital. Journal of Antimicrobial Chemotherapy 1991, 27: 441–457.

    PubMed  Google Scholar 

  63. Hammani A, Arlet G, Ben Redjeb S, Fournier G, Ben Hassen A, Rekik A, Philippon A: Nosocomial outbreak of acute gastroenteritis caused by multiply drugresistantSalmonella wien producing SHV-2 β-lactamase in a neonatal intensive care unit. European Journal of Clinical Microbiology and Infectious Diseases 1991, 10: 641–646.

    Article  Google Scholar 

  64. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak ofKlebsiella infection resistant to late-generation cephalosporins. Annals of Internal Medicine 1993, 119: 353–358.

    CAS  PubMed  Google Scholar 

  65. Rasmussen BA, Bradford PA, Quinn JP, Wiener J, Weinstein RA, Bush K: Genetically diverse ceftazidimeresistant isolates from a single center: biochemical and genetic characterization of TEM-10 β-lactamase encoded by different nucleotide sequences. Antimicrobial Agents and Chemotherapy 1993, 37: 1989–1992.

    CAS  PubMed  Google Scholar 

  66. Rice LB, Willey SH, Papanicoualou GA, Medeiros AA, Eliopoulos GM, Moellering RC, Jacoby GA: Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrobial Agents and Chemotherapy 1990, 34: 2193–2199.

    CAS  PubMed  Google Scholar 

  67. Shannon KP, King A, Phillips I, Nicolas MH, Philippon A: Import of organisms producing broad-spectrum SHV-group beta-lactamases into the United Kingdom. Journal of Antimicrobial Chemotherapy 1990, 25: 343–351.

    CAS  PubMed  Google Scholar 

  68. Jacoby GA, Sutton L: Properties of plasmids responsible for production of extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 1991, 35: 164–169.

    CAS  PubMed  Google Scholar 

  69. Bauernfeind A, Grimm H, Schweighart S: A new plasmidic cefotaximase in a clinical isolate ofEscherichia coli. Infection 1990, 18: 294–298.

    Article  CAS  PubMed  Google Scholar 

  70. Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R: Characterization of a novel extended-spectrum β-lactamase fromPseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1993, 37: 962–969.

    CAS  PubMed  Google Scholar 

  71. Barthélémy M, Péduzzi J, Bernard H, Tancrède C, Labia R: Close amino acid sequence relationship between the new plasmid-mediated extended-spectrum β-lactamase MEN-1 and chromosomally encoded enzymes ofKlebsiella oxytoca. Biochimica et Biophysica Acta 1992, 1122: 15–22.

    PubMed  Google Scholar 

  72. Nordmann P, Naas T: Sequence analysis of PER-1 extended-spectrum β-lactamase fromPseudomonas aeruginosa and comparison with class A β-lactamases. Antimicrobial Agents and Chemotherapy, 1994, 38: 104–114.

    CAS  PubMed  Google Scholar 

  73. Sanders CC: Chromosomal cephalosporinases responsible for multiple resistance to newer β-lactam antibiotics. Annual Review of Microbiology 1987, 41: 573–593.

    Article  CAS  PubMed  Google Scholar 

  74. Sanders CC, Sanders WE: β-lactam resistance in gramnegative bacteria: global trends and clinical impact. Clinical Infectious Diseases 1992, 15: 824–839.

    CAS  PubMed  Google Scholar 

  75. Woodford N, Payne DJ, Johnson AP, Weinbren MJ, Perinpanayagam RM, George RC, Cookson BD, Amyes SGB: Transferable cephalosporin resistance not inhibited by clavulanate inEscherichia coli. Lancet 1990, 336: 253.

    Article  CAS  PubMed  Google Scholar 

  76. Thomson KS, Sanders CC: Detection of extended-spectrum β-lactamases in members of the familyEnterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrobial Agents and Chemotherapy 1992, 36: 1877–1882.

    CAS  PubMed  Google Scholar 

  77. Livermore D: Carbapenemases: the next generation of β-lactamases. ASM News 1993, 59: 129–135.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Bactériologie-Virologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France

    A. Philippon, G. Arlet & P. H. Lagrange

Authors
  1. A. Philippon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Arlet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. H. Lagrange
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Philippon, A., Arlet, G. & Lagrange, P.H. Origin and impact of plasmid-mediated extended-spectrum beta-lactamases. Eur. J. Clin. Microbiol. Infect. Dis. 13 (Suppl 1), S17–S29 (1994). https://doi.org/10.1007/BF02390681

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02390681

Keywords

Search

Navigation